Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 April;55(2) > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 April;55(2):126-54

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

  DOSIMETRY IN NUCLEAR MEDICINE - PART II


The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 April;55(2):126-54

lingua: Inglese

Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab

Sjögreen-Gleisner K. 1, Dewaraja Y. K. 2, Chiesa C. 3, Tennvall J. 4,5, Lindén O. 4,5, Strand S.-E. 1, Ljungberg M. 1

1 Department of Medical Radiation Physics, Lund University, Lund, Sweden;
2 Department of Radiology, University of Michigan, Ann Arbor, MI, USA;
3 Nuclear Medicine Division, National Cancer Institute, IRCCS Foundation Milan, Italy;
4 Department of Oncology, Lund University, Lund, Sweden;
5 Department of Oncology, Skane University Hospital, Lund, Sweden


PDF  


Radioimmunotherapy involves the use of radiolabeled monoclonal antibodies (MAbs) to treat malignancy. The therapeutic effect is determined by the radiopharmaceutical, the radiation absorbed dose and previous treatments. There are currently two approved radiopharmaceuticals for the treatment of B-cell lymphoma – the 90Y-labeled ibritumomab and the 131I-labeled tositumomab. Both are directed against CD20, albeit not against the same epitope. This paper summarizes current results of dose-responses for normal tissues and tumours of [131I]tositumomab and [90Y]ibritumomab tiuxetan, discusses them in the context of dosimetry methods used and highlights the assumptions being made in the different dosimetry methodologies. Moreover, we wish to point at the possibility of performing low-cost therapy bremsstrahlung imaging for [90Y]ibritumomab tiuxetan to confirm biodistribution, and possibly also for dosimetric calculations.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail